NEW TREATMENTS FOR PATIENTS WITH MENTAL ILLNESS
Associate Professor Bernadette Fitzgibbon
Director of Psychiatry Research
Paratus Clinical, Australia &
Associate Professor,
Australian National University, Canberra, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | November 2025
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
She is currently the Director of Psychiatry Research at Paratus Clinical, where she leads the delivery of clinical trials in emerging therapies for psychiatry, collaborating with academic institutions, pharmaceutical and biotechnology companies. She is also an Associate Professor at the Australian National University, where she contributes to novel investigator-initiated trials within interventional psychiatry and clinical neuroscience, and a consultant at The Psychedelic Consultancy: a hub to connect and support professionals navigate the legal psychedelic assisted psychotherapy ecosystem in Australia and internationally. Together, she is dedicated to changing the landscape of mental health treatments to improve the outcomes for people living with mental illness.
Source: Supplied
You Might also like
-
Funding the best brains to beat brain cancer
The Charlie Teo Foundation is dedicated to funding and advancing research into brain cancer, with a particular focus on developing more effective treatments and finding a cure for this devastating disease.
Since its inception, the foundation has committed nearly $15 million to brain cancer research, funding notable projects in Australia and the United States. These projects explore innovative approaches to understand and treat brain cancer more effectively, with a focus on translating findings from animal studies to human applications. Charlie’s dedication to finding solutions for this devastating disease remains unwavering as he travels frequently to collaborate with global researchers. -
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
https://orcid.org/0000-0002-5339-5304